Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non Operating Income (2023 - 2025)

Monte Rosa Therapeutics' Other Non Operating Income history spans 3 years, with the latest figure at -$50000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 2600.0% year-over-year to -$50000.0; the TTM value through Dec 2025 reached $1.5 million, up 256.73%, while the annual FY2025 figure was $1.5 million, 256.73% up from the prior year.
  • Other Non Operating Income reached -$50000.0 in Q4 2025 per GLUE's latest filing, down from -$29000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.4 million in Q2 2025 to a low of -$779000.0 in Q4 2023.
  • Average Other Non Operating Income over 3 years is $80833.3, with a median of -$39500.0 recorded in 2025.
  • The largest YoY upside for Other Non Operating Income was 2722.64% in 2025 against a maximum downside of 2600.0% in 2025.
  • A 3-year view of Other Non Operating Income shows it stood at -$779000.0 in 2023, then skyrocketed by 100.26% to $2000.0 in 2024, then tumbled by 2600.0% to -$50000.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Other Non Operating Income are -$50000.0 (Q4 2025), -$29000.0 (Q3 2025), and $1.4 million (Q2 2025).